Business Description
Shanxi Jinbo Bio pharmaceutical Co Ltd
ISIN : CNE100006392
Compare
Compare
Traded in other countries / regions
832982.China IPO Date
2023-07-20Description
Shanxi Jinbo Bio pharmaceutical Co Ltd is engaged in research & development, production and sales of various medical devices and functional skin care products with recombinant collagen products and anti-HPV biological protein products as the core.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.05 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | 0.36 | |||||
| Interest Coverage | 73.87 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 23.95 | |||||
| Beneish M-Score | -1.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 67.4 | |||||
| 3-Year EBITDA Growth Rate | 95.2 | |||||
| 3-Year EPS without NRI Growth Rate | 97.5 | |||||
| 3-Year FCF Growth Rate | 30.6 | |||||
| 3-Year Book Growth Rate | 41.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 41.99 | |||||
| Future 3-5Y Total Revenue Growth Rate | 44.62 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.48 | |||||
| 9-Day RSI | 43.75 | |||||
| 14-Day RSI | 44.97 | |||||
| 6-1 Month Momentum % | 48.07 | |||||
| 12-1 Month Momentum % | -14.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.69 | |||||
| Quick Ratio | 3.4 | |||||
| Cash Ratio | 2.69 | |||||
| Days Inventory | 266.41 | |||||
| Days Sales Outstanding | 36.62 | |||||
| Days Payable | 229.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.96 | |||||
| Dividend Payout Ratio | 0.32 | |||||
| Forward Dividend Yield % | 1.2 | |||||
| 5-Year Yield-on-Cost % | 0.96 | |||||
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | 0.98 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.98 | |||||
| Operating Margin % | 59.99 | |||||
| Net Margin % | 50.13 | |||||
| FCF Margin % | 43.01 | |||||
| ROE % | 58.46 | |||||
| ROA % | 40.05 | |||||
| ROIC % | 76.76 | |||||
| ROC (Joel Greenblatt) % | 116.85 | |||||
| ROCE % | 57.89 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.76 | |||||
| Forward PE Ratio | 21.03 | |||||
| PE Ratio without NRI | 26.58 | |||||
| Shiller PE Ratio | 163.16 | |||||
| Price-to-Owner-Earnings | 34.93 | |||||
| PEG Ratio | 0.76 | |||||
| PS Ratio | 13.72 | |||||
| PB Ratio | 14.01 | |||||
| Price-to-Tangible-Book | 15.01 | |||||
| Price-to-Free-Cash-Flow | 33.67 | |||||
| Price-to-Operating-Cash-Flow | 27.05 | |||||
| EV-to-EBIT | 24.06 | |||||
| EV-to-EBITDA | 24.06 | |||||
| EV-to-Revenue | 14.31 | |||||
| EV-to-FCF | 33.27 | |||||
| Price-to-Projected-FCF | 9.79 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.89 | |||||
| Price-to-Graham-Number | 4.21 | |||||
| Price-to-Net-Current-Asset-Value | 31.69 | |||||
| Price-to-Net-Cash | 65.98 | |||||
| Earnings Yield (Greenblatt) % | 4.16 | |||||
| FCF Yield % | 2.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanxi Jinbo Bio pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,251.608 | ||
| EPS (TTM) (Â¥) | 7.791 | ||
| Beta | 2.06 | ||
| Volatility % | 51.27 | ||
| 14-Day RSI | 44.97 | ||
| 14-Day ATR (Â¥) | 10.930145 | ||
| 20-Day SMA (Â¥) | 214.6805 | ||
| 12-1 Month Momentum % | -14.38 | ||
| 52-Week Range (Â¥) | 142.6 - 293.62 | ||
| Shares Outstanding (Mil) | 88.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanxi Jinbo Bio pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanxi Jinbo Bio pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanxi Jinbo Bio pharmaceutical Co Ltd Frequently Asked Questions
What is Shanxi Jinbo Bio pharmaceutical Co Ltd(BJSE:832982)'s stock price today?
The current price of BJSE:832982 is ¥208.50. The 52 week high of BJSE:832982 is ¥293.62 and 52 week low is ¥142.60.
When is next earnings date of Shanxi Jinbo Bio pharmaceutical Co Ltd(BJSE:832982)?
The next earnings date of Shanxi Jinbo Bio pharmaceutical Co Ltd(BJSE:832982) is .
Does Shanxi Jinbo Bio pharmaceutical Co Ltd(BJSE:832982) pay dividends? If so, how much?
The Dividend Yield %  of Shanxi Jinbo Bio pharmaceutical Co Ltd(BJSE:832982) is 0.96% (As of Today), Highest Dividend Payout Ratio of Shanxi Jinbo Bio pharmaceutical Co Ltd(BJSE:832982) was 0.32. The lowest was 0.11. And the median was 0.11. The  Forward Dividend Yield % of Shanxi Jinbo Bio pharmaceutical Co Ltd(BJSE:832982) is 1.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers